Friday 6 November 2026 Export RDY’s income statement to Excel — free account

Dr. Reddy's Laboratories Ltd

RDY Healthcare Drug Manufacturers Specialty & Generic

Dr. Reddy's Laboratories Ltd’s revenue for fiscal 2026 (year ended March 2026) was $3.6 billion, down 6.06% from fiscal 2025.

Revenue: −10.1%
EPS: −36.8%
Free cash flow: −70.5%
Total debt: +14.1%

Quarter to September 2026, against a year earlier

14.53 0.24 −1.62%

Follow RDY

Alert me

Market cap: $12.1B
P/E: 44.4×
Fwd P/E: 30.7×
Dividend yield: 0.00%
F-score: 4/9
Altman Z: 5.26
Beneish M: −2.59
Dividend safety: 74/100

Overview

Dr. Reddy's Laboratories Ltd (RDY) P/B ratio

Alert me on P/B ratio

As of 5 November 2026, Dr. Reddy's Laboratories Ltd (RDY) trades at a P/B ratio of 3.0×. Over the past ten years it has ranged from 2.2× (July 2026) to 18.0× (October 2024); the current reading is higher than 21% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 1.8× and above the Healthcare sector median of 2.3×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/RDY/pb-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Dr. Reddy&#39;s Laboratories Ltd P/B ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/RDY/metrics/pb-ratio">Dr. Reddy&#39;s Laboratories Ltd (RDY) P/B ratio — stockrow.com</a></p>

Period	P/B ratio	Change
FY2026	2.8×	2.17%
FY2025	2.8×	(23.86%)
FY2024	3.7×	8.67%
FY2023	3.4×	(8.70%)
FY2022	3.7×	(14.39%)
FY2021	4.3×	32.23%
FY2020	3.3×	(1.99%)
FY2019	3.3×	20.14%
FY2018	2.8×	(21.01%)
FY2017	3.5×	(12.02%)

Period	P/B ratio	Change
Sep 2026	2.6×	(6.95%)
Jun 2026	2.8×	(2.30%)
Mar 2026	2.8×	1.76%
Dec 2025	2.8×	(2.12%)
43 more quarters	Free account

Against its own ten years

Low 2.2× High 18.0×

Ten-year median 3.6×

Current reading's percentile 23

Company	P/B ratio
VTRS Viatris Inc. compare	1.6×
ELAN Elanco Animal Health Incorporated compare	1.8×
RDY Dr. Reddy's Laboratories Ltd	3.0×
ALKS Alkermes plc compare	4.0×
NBIX Neurocrine Biosciences, Inc. compare	4.2×
LNTH Lantheus Holdings, Inc. compare	4.9×
KNSA Kiniksa Pharmaceuticals International, plc compare	9.7×
HIMS Hims & Hers Health, Inc. compare	17.2×
AMRX AMNEAL PHARMACEUTICALS, INC. compare	59.5×
Drug Manufacturers Specialty & Generic industry median	1.8×
Healthcare sector median	2.3×
Market median	1.7×

What P/B ratio is

Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.

Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))

The full definition of P/B ratio →

Dr. Reddy's Laboratories Ltd (RDY) P/B ratio

P/B ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/B ratio against peers

What P/B ratio is

More on RDY

P/B ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/B ratio against peers

What P/B ratio is

More on RDY

Stockrow Weekly